Sfoglia per Autore
Mantle zone lymphoma: an immunohistologic study of skin lesions.
1994-01-01 M. BERTERO; M. NOVELLI; M.T. FIERRO; M.G. BERNENGO
La sindrome di Sézary.
1994-01-01 BERNENGO M.G.; NOVELLI M; QUAGLINO P; FIERRO MT.
Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
1993-01-01 M.T. FIERRO; M. BERTERO; M. NOVELLI; A. APPINO; G.C. DOVEIL; S. COLONNA; M.G. BERNENGO
Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical application.
1993-01-01 BERNENGO MG; FIERRO MT; NOVELLI M; LISA F; APPINO A
In vitro functional studies on sIL-2R release by Sézary cells
1992-01-01 Appino A; Fierro MT; Novelli M; Lisa F; Bernengo MG
Functional studies on sIL-2R release by Sezary cells
1992-01-01 Appino A; Fierro mT; Novelli M; Lisa F; Bernengo MG
Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study
1992-01-01 FIERRO MT; LISA F; M. NOVELLI; BERTERO M; BERNENGO MG
Thymopentin in Sézary syndrome.
1992-01-01 M. BERNENGO; APPINO A; BERTERO M; NOVELLI M; FIERRO MT; DOVEIL GC; LISA F.
Expression and role of integrin receptors in Sézary syndrome.
1992-01-01 SAVOIA P; M. NOVELLI; FIERRO MT; CREMONA O; MARCHISIO PC; BERNENGO MG
sIL-2R, sCD4 AND sCD8 LEVELS IN MELANOMA: A LONGITUDINAL STUDY.
1991-01-01 Fierro M.T.; Lisa F.; Novelli M.; Bertero M.; Bernengo M.G.
Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
1991-01-01 FOA R ;FIERRO MT ;CESANO A ;GUARINI A ;BONFERRONI M ;RASPADORI D ;MINIERO R ;LAURIA F ;GAVOSTO F
Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
1991-01-01 FOA R ;GUARINI A ;GILLIO TOS A ;CARDONA S ;FIERRO MT ;MELONI G ;TOSTI S ;MANDELLI F ;GAVOSTO F
sIL-2R. A useful marker in the melanoma follow-up
1991-01-01 Fierro MT; Lisa F; Novelli M; Bertero M; Bernengo MG.
The integrin heterodimer 3ß1 is expressed in skin but not in peripheral blood Sézary cells.
1991-01-01 Savoia P; Novelli M; Fierro MT; Cremona O; Marchisio PC; Bernengo MG
Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.
1990-01-01 Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Guarini A; Tos AG; di Celle PF; Cesano A; Matera L.
Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin.
1990-01-01 FOA R ;CARETTO P ;FIERRO MT ;BONFERRONI M ;CARDONA S ;GUARINI A ;LISTA P ;PEGORARO L ;MANDELLI F ;FORNI G
Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alpha
1990-01-01 Bellone G; Fierro MT; Liao XS; Tos AG; Bonferroni M; Pegoraro L; Foa R.
Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease.
1990-01-01 FOA' R; M. MASSAIA; CARDONA S; GILLIO TOS A; BIANCHI A; ATTISANO C; GUARINI A; FRANCIA DI CELLE P; FIERRO MT
Lymphokine activated killer (LAK) activity in lymphoproliferative disorders.
1989-01-01 Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Liao XS; Cesano A; Matera L; Gillio Tos A; Tola E; et al.
Immunologic and molecular evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical remission phase.
1989-01-01 BRUGIATELLI M ;CALLEA V ;MORABITO F ;OLIVA B ;FRANCIA DI CELLE P ;FIERRO MT ;NERI A ;FOA R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile